Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Trial details
- Registry ID
- NCT05616221
- Drugs studied
- AP-PA02
TrialRedline tracks 1 clinical trial sponsored by Armata Pharmaceuticals, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionNCT05616221 | AP-PA02 | Completed | 2024-07-17Actual |
Names as written in the registry records.